High-Dose Chemotherapy with Autotransplantation in AL Amyloidosis: A Flawed Meta-analysis

Biology of Blood and Marrow Transplantation

Volumn 16, Issue 1, 2010, Pages 138-140

  Mehta, Jayesh ^a   Dispenzieri, Angela ^b   Gertz, Morie A ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; DOXORUBICIN; VINCRISTINE;

AMYLOIDOSIS; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CLINICAL PRACTICE; CLINICAL TRIAL; EVIDENCE BASED MEDICINE; HUMAN; LETTER; LONG TERM CARE; MEDICAL DECISION MAKING; META ANALYSIS; MORTALITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT SELECTION; SURVIVAL TIME; SYSTEMATIC REVIEW;

AMYLOIDOSIS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; META-ANALYSIS AS TOPIC; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 72649086331     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2009.09.005     Document Type: Letter

References (14)

1. Mhaskar R, Kumar A, Behara M, Kharfan-Dabaja MA, Djulbegovic B. Role of high-dose chemotherapy and autologous hematopoietic cell transplantation in primary systemic amyloidosis: a systematic review. Biol Blood Marrow Transplant. doi:10.1016/j.bbmt.2009.01.022.
2. Dispenzieri A., Kyle R.A., Lacy M.Q., et al. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood 103 (2008) 3960-3963
3. Dispenzieri A., Lacy M.Q., Kyle R.A., et al. Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. J Clin Oncol 19 (2001) 3350-3356
4. Mehta J. High-dose therapy for amyloidosis: the end of the beginning?. Blood 103 (2004) 3612-3613
5. Gono T., Matsuda M., Shimojima Y., et al. VAD with or without subsequent high-dose melphalan followed by autologous stem cell support in AL amyloidosis: Japanese experience and criteria for patient selection. Amyloid 11 (2004) 245-256
6. Van Gameren II, Hazenberg B.P., Jager P.L., et al. AL amyloidosis treated with induction chemotherapy with VAD followed by high-dose melphalan and autologous stem cell transplantation. Amyloid 9 (2002) 165-174
7. Jaccard A., Moreau P., Leblond V., et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 357 (2007) 1083-1093
8. Kumar S., Dispenzieri A., and Gertz M.A. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 358 (2008) 91
9. Mehta J. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 358 (2008) 91
10. Mehta J. Amyloidosis: graviores morbos, asperis remedii. Blood 110 (2007) 3490-3491
11. Gertz M., Lacy M., Dispenzieri A., et al. Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis. Leuk Lymphoma 49 (2008) 36-41
12. Sanchorawala V., Skinner M., Quillen K., Finn K.T., Doros G., and Seldin D.C. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation. Blood 110 (2007) 3561-3563
13. Kumar A., Kharfan-Dabaja M.A., Glasmacher A., and Djulbegovic B. Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis. J Natl Cancer Inst 101 (2009) 100-106
14. Mehta J. Tandem vs single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis J Natl Cancer Inst. In press.